Disease · MONDO_0019355
adult-onset Still disease
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. adult-onset Still disease. Diseases, record MONDO_0019355. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019355
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- AOSD, Adult-Onset Still's Disease, Still's Disease, Adult-Onset, Wissler-Fanconi syndrome
- Open Targets
Drugs14
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ANAKINRA | CHEMBL1201570 | Protein | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CANAKINUMAB | CHEMBL1201834 | Antibody | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| GOFLIKICEPT | CHEMBL4650513 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| AZATHIOPRINE | CHEMBL1542 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CYCLOSPORINE | CHEMBL160 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EMAPALUMAB | CHEMBL3989977 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LEFLUNOMIDE | CHEMBL960 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| RILONACEPT | CHEMBL1201830 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SULFASALAZINE | CHEMBL421 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 14
See all 14 drugsTargets13
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| IL18 | Interleukin-18 | 2 | Interleukin-18 cross-linking agent; Interleukin-18 inhibitor | Phase 2 | https://conductscience.org/library/genes/3606 | Drugs and targets |
| IL1B | Interleukin-1 beta | 2 | Interleukin-1 beta inhibitor | Phase 3 | https://conductscience.org/library/genes/3553 | Drugs and targets |
| ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | 1 | Arachidonate 5-lipoxygenase inhibitor | Phase 2 | https://conductscience.org/library/genes/240 | Drugs and targets |
| DHFR | Dihydrofolate reductase | 1 | Dihydrofolate reductase inhibitor | Phase 2 | https://conductscience.org/library/genes/1719 | Drugs and targets |
| DHODH | Dihydroorotate dehydrogenase (quinone), mitochondrial | 1 | Dihydroorotate dehydrogenase inhibitor | Phase 2 | https://conductscience.org/library/genes/1723 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Unknown | https://conductscience.org/library/genes/2280 | Drugs and targets |
| IFNG | Interferon gamma | 1 | Interferon gamma inhibitor | Phase 2 | https://conductscience.org/library/genes/3458 | Drugs and targets |
| IL1R1 | Interleukin-1 receptor type 1 | 1 | Interleukin-1 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/3554 | Drugs and targets |
| IL6R | Interleukin-6 receptor subunit alpha | 1 | Interleukin-6 receptor alpha subunit inhibitor | Phase 2 | https://conductscience.org/library/genes/3570 | Drugs and targets |
| PPAT | Amidophosphoribosyltransferase | 1 | Amidophosphoribosyltransferase inhibitor | Phase 2 | https://conductscience.org/library/genes/5471 | Drugs and targets |
1 to 10 of 13
See all 13 targetsTrials14
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02204293 | Canakinumab for Treatment of Adult-onset Still's Disease | Phase 2 | 36 | 2020-08-07 | Adult-Onset Still´s Disease | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03311854 | A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH) | Phase 2 | 14 | 2022-01-26 | Macrophage Activation Syndrome, Lymphohistiocytosis, Hemophagocytic, Arthritis, Juvenile, Adult Onset Still Disease | EMAPALUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03265132 | A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD) | Phase 3 | 13 | 2020-04-28 | Still's Disease, Adult-Onset, Still's Disease, Juvenile-Onset | ANAKINRA | Its record names the disease | ClinicalTrials.gov |
| NCT00094900 | Interleukin-1 Trap to Treat Autoinflammatory Diseases | Phase 2 | 11 | 2013-07-10 | Inflammation, Familial Mediterranean Fever, Still's Disease, Adult-Onset | RILONACEPT | Its record names the disease | ClinicalTrials.gov |
| NCT06497491 | An Efficacy and Safety Study of GNR-086 (Canakinumab Biosimilar) and Ilaris® in Patients With Adult-onset Still's Disease | Phase 3 | 118 | Still's Disease Adult Onset | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT01033656 | Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study | Phase 2 | 23 | Adult-Onset Still's Disease | ANAKINRA, AZATHIOPRINE, CYCLOSPORINE, LEFLUNOMIDE, METHOTREXATE, SULFASALAZINE | Its record names the disease | ClinicalTrials.gov | |
| NCT02398435 | Therapeutic Use of Tadekinig Alfa in Adult-onset Still's Disease | Phase 2 | 23 | Still's Disease, Adult-Onset | TADEKINIG ALFA | Its record names the disease | ClinicalTrials.gov | |
| NCT07191444 | A Study of Firsekibart Versus Anakinra in Adult-Onset Still's Disease | 20 | Still's Disease, Adult-Onset | ANAKINRA | Its record names the disease | ClinicalTrials.gov | ||
| NCT05814159 | A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD) | Phase 3 | 15 | Still's Disease, Juvenile Onset, Still's Disease, Adult-Onset | ANAKINRA | Its record names the disease | ClinicalTrials.gov | |
| NCT04717635 | Study of Efficacy and Safety of Canakinumab in Japanese Patients With AOSD | Phase 3 | 14 | Adult Onset Still's Disease | CANAKINUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 14
See all 14 trialsComparisons in its trials28
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Anakinra vs Placebo: Proportion of Patients With Macrophage Activation Syndrome (MAS). | 0 of 6 | 0 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With Antidrug Antibodies (ADA) Against Anakinra. | 6 of 6 | 1 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With Neutralizing Antibodies. | 0 of 6 | 0 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With at Least One Serious Adverse Event Including Death. | 0 of 6 | 1 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Patients With at Least One Adverse Event. | 6 of 6 | 4 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: deaths from any cause | 0 of 6 | 0 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: serious adverse events | 0 of 6 | 1 of 6 | 12 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of Responders in Assessment of Physical Function (CHAQ/SHAQ). | 4 of 6 | 0 of 5 | 11 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of ACR70 Responders With Absence of Fever During 24 Hours Preceding Week 1. | 5 of 6 | 0 of 5 | 11 | NCT03265132 | Trial comparisons |
| Anakinra vs Placebo: Proportion of ACR90 Responders With Absence of Fever During 24 Hours Preceding Week 1. | 4 of 6 | 0 of 5 | 11 | NCT03265132 | Trial comparisons |
1 to 10 of 28
See all 28 comparisons in its trialsPapers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019355
GET https://conductscience.org/api/diseases/v1/MONDO_0019355/comparisons?page=2